Reading all of these studies, I always see that they have progression free survival. My father is on month 10 right now using zytiga and his PSA ticked up from <0.02 and now is at a 0.06. This would put him on the short end of the stick if this is defined as PSA progression. Yet, I've read that PSA progression is defined as an increase of >25% over nadir but has to be above 2.0 PSA. I've just read a study that most men on zytiga have stayed on it, even when their PSA had risen by greater than 50 points of PSA.
So I was just wondering when people who were hormone sensitive switched treatments. My father has anemia from systemic mastocytosis so I want him to ride the zytiga or xtandi train as long as possible.